secwatch.observer — SEC 8-K summary
======================================

Issuer:     REGENXBIO Inc. (RGNX)
CIK:        0001590877
Form:       8-K
Filed at:   2026-03-20T23:59:59+00:00
Accession:  0001193125-26-117913
Event type: litigation
Sentiment:  neutral
Materiality: 0.60
Item codes: 1.01
LLM model:  deepseek-v4-flash:cloud@v2

REGENXBIO settles GSK sublicense fee dispute for $10M
-----------------------------------------------------

- Company will pay $10.0M to GSK within 3 business days for alleged underpayment of sublicense fees.
- Settlement includes mutual releases of past claims and certain future claims under the 2009 license agreement.
- Company retains existing allocation methodology for future sublicense fee payments to GSK.
- Dispute covered sublicense fees and royalties on amounts received from sublicensees.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1590877/000119312526117913/0001193125-26-117913-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1590877/000119312526117913/rgnx-20260318.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-117913

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer